Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Jun;13(6):841–846. doi: 10.1111/j.1365-2125.1982.tb01876.x

Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.

R G Wilcox, J R Hampton
PMCID: PMC1402028  PMID: 6124268

Abstract

1 The effects of 4 week treatment periods of once-daily atenolol 100 mg, nadolol 80 mg, nadolol 160 mg and placebo on resting and exercise heart rate and blood pressure were compared in a single-blind crossover trial in fifteen patients with essential hypertension. 2 Both atenolol and nadolol, irrespective of dose, reduced resting and exercise blood pressures to the same extent. 3 Nadolol caused a greater bradycardia both at rest and during exercise than did atenolol, thereby effecting a greater reduction in double-product. 4 During progressive treadmill exercise neither atenolol nor nadolol prevented a linear increase in heart rate and blood pressure which were parallel to, but at a lower level than, that produced by placebo. 5 In each individual patient the magnitude of the hypotensive effect produced by one drug was similar to that produced by the other. 6 All the treatment periods resulted in the same linear increase in the patients' perceived exertion scores during exercise despite marked differences in haemodynamic responses evoked by the beta-adrenoceptor blockers compared with placebo. 7 Neither atenolol or nadolol produced any significant change in peak expiratory flow rate compared with placebo.

Full text

PDF
841

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amery A., De Plaen J. F., Lijnen P., McAinsh J., Reybrouck T. Relationship between blood level of atenolol and pharmacologic effect. Clin Pharmacol Ther. 1977 Jun;21(6):691–699. doi: 10.1002/cpt1977216691. [DOI] [PubMed] [Google Scholar]
  2. Bengtsson C., Johnsson G., Regårdh C. G. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther. 1975 Apr;17(4):400–408. doi: 10.1002/cpt1975174400. [DOI] [PubMed] [Google Scholar]
  3. Brown H. C., Carruthers S. G., Johnston G. D., Kelly J. G., McAinsh J., McDevitt D. G., Shanks R. G. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther. 1976 Nov;20(5):524–534. doi: 10.1002/cpt1976205524. [DOI] [PubMed] [Google Scholar]
  4. Bruce R. A. Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation. Ann Clin Res. 1971 Dec;3(6):323–332. [PubMed] [Google Scholar]
  5. Douglas-Jones A. P., Cruickshank J. M. Once-daily dosing with Atenolol in patients with mild or moderate hypertension. Br Med J. 1976 Apr 24;1(6016):990–991. doi: 10.1136/bmj.1.6016.990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dreyfuss J., Griffith D. L., Singhvi S. M., Shaw J. M., Ross J. J., Jr, Vukovich R. A., Willard D. A. Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients. J Clin Pharmacol. 1979 Nov-Dec;19(11-12):712–720. doi: 10.1002/j.1552-4604.1979.tb01641.x. [DOI] [PubMed] [Google Scholar]
  7. Duchin K. L., Vukovich R. A., Dennick L. G., Groel J. T., Willard D. A. Effects of nadolol beta-blockade on blood pressure in hypertension. Clin Pharmacol Ther. 1980 Jan;27(1):57–63. doi: 10.1038/clpt.1980.9. [DOI] [PubMed] [Google Scholar]
  8. Evans D. B., Peschka M. T., Lee R. J., Laffan R. J. Anti-arrhythmic action of nadolol, a beta-adrenergic receptor blocking agent. Eur J Pharmacol. 1976 Jan;35(1):17–27. doi: 10.1016/0014-2999(76)90296-x. [DOI] [PubMed] [Google Scholar]
  9. Frithz G. Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertension. Curr Med Res Opin. 1978;5(5):383–387. doi: 10.1185/03007997809111902. [DOI] [PubMed] [Google Scholar]
  10. Hill L. S., Fand R. S. A report on the clinical efficacy of nadolol--a new long acting beta-blocker. Ir Med J. 1979 Dec;72(12):522–529. [PubMed] [Google Scholar]
  11. Hitzenberger G. Initial experience with a new long-acting beta-blocker, nadolol, in hypertensive patients. J Int Med Res. 1979;7(1):33–38. doi: 10.1177/030006057900700105. [DOI] [PubMed] [Google Scholar]
  12. Jeffers T. A., Webster J., Petrie J. C., Barker N. P. Atenolol once-daily in hypertension. Br J Clin Pharmacol. 1977 Oct;4(5):523–527. doi: 10.1111/j.1365-2125.1977.tb00780.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lee R. J., Evans D. B., Baky S. H., Laffan R. J. Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression. Eur J Pharmacol. 1975 Sep-Oct;33(2):371–382. doi: 10.1016/0014-2999(75)90182-x. [DOI] [PubMed] [Google Scholar]
  14. Marshall A. J., Barritt D. W., Heaton S., Harry J. D. Dose response for blood pressure and degree of cardiac beta-blockade with atenolol. Postgrad Med J. 1979 Sep;55(646):537–540. doi: 10.1136/pgmj.55.646.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McAinsh J. Clinical pharmacokinetics of atenolol. Postgrad Med J. 1977;53 (Suppl 3):74–78. [PubMed] [Google Scholar]
  16. McDevitt D. G., Shand D. G. Plasma concentrations and the time-course of beta blockade due to propranolol. Clin Pharmacol Ther. 1975 Dec;18(6):708–713. doi: 10.1002/cpt1975186708. [DOI] [PubMed] [Google Scholar]
  17. Melander A., Stenberg P., Liedholm H., Scherstén B., Wåhlin-Boll E. Food-induced reduction in bioavailability of atenolol. Eur J Clin Pharmacol. 1979 Nov;16(5):327–330. doi: 10.1007/BF00605630. [DOI] [PubMed] [Google Scholar]
  18. Pearson S. B., Banks D. C., Patrick J. M. The effect of beta-adrenoceptor blockade on factors affecting exercise tolerance in normal man. Br J Clin Pharmacol. 1979 Aug;8(2):143–148. doi: 10.1111/j.1365-2125.1979.tb05812.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Shand D. G. Individualization of propranolol therapy. Med Clin North Am. 1974 Sep;58(5):1063–1069. doi: 10.1016/s0025-7125(16)32102-2. [DOI] [PubMed] [Google Scholar]
  20. Vukovich R. A., Foley J. E., Brown B., Willard D. A., Buckley M., O'Kelly D., Fitzgerald D., Tormey W., Darragh A. Effect of beta-blockers on exercise double product (systolic blood pressure x heart rate). Br J Clin Pharmacol. 1979;7 (Suppl 2):167S–172S. doi: 10.1111/j.1365-2125.1979.tb04687.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Watson R. D., Stallard T. J., Littler W. A. Influence of once-daily administration of beta-adrenoceptor antagonists on arterial pressure and its variability. Lancet. 1979 Jun 9;1(8128):1210–1213. doi: 10.1016/s0140-6736(79)91896-8. [DOI] [PubMed] [Google Scholar]
  22. Wilcox R. G., Hampton J. R. Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension. Br Heart J. 1981 Nov;46(5):498–502. doi: 10.1136/hrt.46.5.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wilcox R. G. Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. Br Med J. 1978 Aug 5;2(6134):383–385. doi: 10.1136/bmj.2.6134.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Williams E. M., Hassan M. O., Floras J. S., Sleight P., Jones J. V. Adaptation of hypertensives to treatment with cardioselective and non-selective beta-blockers. Absence of correlation between bradycardia and blood pressure control, and reduction in slope of the QT/RR relation. Br Heart J. 1980 Nov;44(5):473–487. doi: 10.1136/hrt.44.5.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wilson M., Morgan G., Morgan T. The effect on blood pressure of beta-adrenoceptor blocking drugs administered once daily and their duration of action when therapy is ceased. Br J Clin Pharmacol. 1976 Oct;3(5):857–861. doi: 10.1111/j.1365-2125.1976.tb00638.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES